OncoVista Innovative Therapies, Inc.
OncoVista Innovative Therapies, Inc. (OVIT) Revenue
Annual & quarterly revenue history · segment & region breakdown
OVIT · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsOncoVista Innovative Therapies, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2014.
Revenue trend
2014 – 2004 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | +$0.00B | — |
| 2012-12-31 | $0.00B | +$0.00B | — |
| 2011-12-31 | $0.00B | +$0.00B | — |
| 2010-12-31 | $0.00B | +$0.00B | — |
| 2009-12-31 | $0.00B | -$0.00B | -100.00% |
| 2008-12-31 | $0.00B | -$0.00B | -72.36% |
| 2007-12-31 | $0.00B | -$0.00B | -5.52% |
| 2006-12-31 | $0.00B | +$0.00B | +1199.95% |
| 2005-12-31 | $0.00B | +$0.00B | +90.11% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income OncoVista Innovative Therapies, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
OncoVista Innovative Therapies, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from OncoVista Innovative Therapies, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OVIT revenue · 4 questionsOVIT's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2014.
▸ Source: FMP · OncoVista Innovative Therapies, Inc. SEC filings · GAAP · OncoVista Innovative Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026